Please update your browser.
April 17, 2023
The Secured Overnight Financing Rate (SOFR) will soon replace the U.S. dollar LIBOR (London Interbank Offered Rate), which will cease on a representative basis on June 30, 2023. This will mark the culmination of close to a decade’s work by the Alternate Reference Rate Committee (ARRC), the Official Sector and market participants globally.
SOFR Is Well Established Across Markets
SOFR markets continued to develop throughout 2022. On average, SOFR swaps now account for more than 85% of daily volumes of interest rate risk traded in the outright linear swaps market. In 2023 alone, the total volume of trades referencing SOFR (by notional) currently stands at over $14 trillion, including $1.4 trillion of basis swaps.1 In exchange-traded derivatives, the average daily trading volume of SOFR futures is now roughly three times that of Eurodollar futures — up from less than a quarter at the start of 2022.2 In recent months, J.P. Morgan has seen a significant increase in clients seeking to transition legacy U.S. dollar LIBOR portfolios to SOFR in order to take advantage of this market liquidity.
Ben Kinney, Global Co-Head of Interest Rates Sales
In cash markets, the use of SOFR is now prevalent, comprising over 95% of all new floating rate notes (FRN) issuance and the vast majority of agency-issued adjustable rate mortgages.3 In the loans market, Term SOFR is the predominant rate used in new lending — especially across multi-lender facilities, middle market and trade finance loans. In addition, since the beginning of 2023, the pace of borrowers choosing to proactively restructure to SOFR ahead of cessation has increased.
Patricia Devine, North America Head of Global Corporate Banking
Legislative Initiatives
In December 2022, statutory fallback rates for U.S.-governed law contracts in scope of the LIBOR Act were confirmed by the Federal Reserve Board (FRB).4 The announcement specified fallback rates that will be applied to non-remediated contracts after cessation. For derivatives, statutory fallbacks will follow the International Swaps and Derivatives Association’s (ISDA) IBOR fallback methodology. For the majority of cash products, fallback will be consistent with the Alternative Reference Rates Committee’s (ARRC) hardwired approach.
Greg Geffen, Head of North America Corporate Interest Rate Derivatives
Outside of the U.S., the Financial Conduct Authority (FCA) in the U.K. has confirmed that one-, three- and six-month tenors of U.S. dollar LIBOR will continue to be published based on a non-representative “synthetic” methodology until the end of September 2024.5 This is similar to the approach taken following the cessation of sterling and yen LIBOR at the end of 2021, and will be available for use in all contracts where fallbacks do not contain so-called “non-representative” triggers. This rate is not for use in new products, but it provides time for non-remediated contracts to mature or for parties to agree terms to restructure to SOFR.
Ben Kinney, Global Co-Head of Interest Rates Sales
Entering the Final Quarter
As we enter the final three months prior to cessation, operational work across the industry has intensified. Over two weekends in April and May, over $60 trillion of cleared derivative contracts will convert to SOFR contracts in a process orchestrated by central counterparty clearing houses. Firms are also preparing to conduct the rebooking of products to fallback rates, which will take place at the first fixing post-cessation. These two activities will represent major milestones in firms’ book of work for 2023.
As discussed above, legislative initiatives will apply to all non-remediated contracts and are dependent upon product, governing law and existing contractual provisions. Counterparties should not consider remediation complete with the confirmation of these initiatives. In fact, where clients have non-remediated contracts in their portfolios, it places further emphasis on the need for a comprehensive analysis of fallbacks to ensure they are correctly applied at cessation.
With differing fallback methodologies due to be applied to products at cessation, firms should be prepared to manage basis across fallen-back products in their portfolio. This is especially important for firms that are accounting-sensitive, and presents new challenges where basis risk management was not previously an issue.
Proactive restructuring of portfolios ahead of cessation provides benefits to clients who seek to reduce the operational burden of transition, and who wish to avoid basis risk across fallen-back products post-cessation. Transitioning products to take advantage of SOFR liquidity now removes the risk of potentially dealing in illiquid legacy contracts that may be difficult to unwind over time.
Patricia Devine, North America Head of Global Corporate Banking
We note that proactive restructuring of U.S. dollar LIBOR portfolios ahead of cessation remains the Official Sector’s recommended course of action. We continue to urge market participants to assess their remaining U.S. dollar LIBOR referencing portfolios and ensure they have a strategy in place. As always, J.P. Morgan stands ready to support and guide our clients through the transition process.
Related Insights
Market Matters | Leaving LIBOR Part VI: The End Is In Sight

Market Matters | Leaving LIBOR Part VI: The End Is In Sight
In this podcast episode, we discuss the continued development of derivative and cash Secured Overnight Financing Rate (SOFR) markets.
Markets

Markets
Market-leading research and trade execution across multiple asset classes, including credit, equities and FX.
IBOR Reform Frequently Asked Questions

IBOR Reform Frequently Asked Questions
Key questions to help you prepare for the transition.
1.ARRC Meeting readout - March
2.FSB Progress Report on LIBOR and Other Benchmarks Transition Issues
3.ARRC Meeting - March
4. Federal Reserve Press Release
5.https://www.fca.org.uk/news/news-stories/fca-announces-decision-synthetic-us-dollar-libor
SALES AND TRADING DISCLAIMER
FOR INSTITUTIONAL & PROFESSIONAL CLIENTS ONLY – This material is from a Sales and Trading department and is not a product of the Research Department.
This material has been prepared by personnel in the Sales and Trading Departments of one or more affiliates of JPMorgan Chase & Co. (together, “J.P. Morgan”) and not by J.P. Morgan’s Research Department and therefore, has not been prepared in accordance with legal requirements to promote the independence of research, including but not limited to, the prohibition on the dealing ahead of the dissemination of investment research. It is not a research report and is not intended as such. It is for distribution to institutional and professional clients only and is not intended for retail customer use.
It is provided on a confidential basis and may not be reproduced, redistributed or disseminated, in whole or in part, without the prior written consent of J.P. Morgan. Any unauthorized use is strictly prohibited.
Unless otherwise specifically stated, any views or opinions expressed herein are solely those of the individual author and/or the specific Sales and Trading area from which it originates and may differ from the views or opinions expressed by other areas of J.P. Morgan, including the Research Department.
This material is provided for information purposes only and does not bind J.P. Morgan in any way. It is not intended as a recommendation (except to the extent it is an “investment recommendation” under MAR (as defined below)) or an offer or solicitation (except to the extent covered by CFTC Rules (as defined below)) for the purchase or sale of any security or financial instrument, or to enter into a transaction involving any financial instrument or trading strategy, or as an official confirmation or official valuation of any transaction mentioned herein. Any pricing information provided is indicative only and does not reflect a level where J.P. Morgan is prepared to execute a trade. J.P. Morgan is not an advisor. Nothing in this material should be construed as investment, tax, legal, accounting, regulatory or other advice (including within the meaning of Section 15B of the Securities Exchange Act of 1934) or as creating a fiduciary relationship.
MAR Disclosure: Where this material is an “investment recommendation” as that term is defined in Article 3(1)(35) of the EU and UK Market Abuse Regulation (“MAR”), distribution of this material is subject to the relevant provisions of MAR. For more information, please consult: www.jpmm.com/#mardisclosures.
Research Disclosure: This material is not, and is not intended to be, a “research report”, “investment research” or “independent research” as may be defined in applicable laws and regulations worldwide. However, it may constitute “research” as defined in Recital 28 of the Commission Delegated Directive (EU) 2017/593 and in the Financial Conduct Authority’s Handbook.
Derivatives Disclosure: Where distribution of this material is subject to the rules of the U.S. Commodity Futures Trading Commission (“CFTC”), it is a “solicitation” of derivatives business generally only as that term is used within CFTC Rule 1.71 and 23.605 promulgated under the U.S. Commodity Exchange Act (the “CFTC Rules”).
Options Disclosure: Structured securities, options, futures and other derivatives are complex instruments and may involve a high degree of risk. Before entering into any such transactions, please ensure that you have read and understood the Options Clearing Corporation’s Characteristics and Risks of Standardized Options, also known as the options disclosure document (ODD) available at: http://www.theocc.com/about/publications/character-risks.jsp.
Exchange Traded Fund (“ETF”) Disclosure: Each U.S. registered ETF has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission. Each non-U.S. ETF will have its own offering documents as required by applicable law. No offer or sale of the ETFs described may be made except pursuant to the prospectus or offering documents, as applicable. The ETF’s prospectus and/or offering documents are available through the ETF issuer’s website; you should read these carefully before deciding to invest.
Transactions involving securities, financial instruments and strategies mentioned herein may not be suitable for all investors. You are solely responsible for deciding whether any investment or transaction is suitable for you based upon your investment goals, financial situation and tolerance for risk. If you deem it necessary, you must seek independent professional advice to ascertain the investment, legal, tax, accounting, regulatory or other consequences before investing or transacting.
Past or simulated past performance (including back-testing) is not indicative of future results. The investments discussed may fluctuate in price or value. Changes in rates of exchange may have an adverse effect on the value of investments. Any modelling, scenario analysis or other forward-looking information herein (such as projected cashflows, yields or returns) is intended to illustrate hypothetical results based on certain assumptions (not all of which will be specified herein). Actual events or conditions may differ materially from those assumed; therefore, actual results are not guaranteed.
All market prices, data and other information (including that which may be derived from third party sources believed to be reliable) are not warranted as to completeness or accuracy and are subject to change without notice. J.P. Morgan disclaims any responsibility or liability to the fullest extent permitted by applicable law, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. The information contained herein is as of the date and time referenced only, and J.P. Morgan does not undertake any obligation to update such information.
J.P. Morgan may have positions (long or short), effect transactions or make markets in securities or financial instruments mentioned herein (or related instruments), or provide advice or loans to, or participate in the underwriting or restructuring of the obligations of, the legal entities mentioned herein. The Sales and Trading personnel who prepared this material may be compensated in part based on trading activity. Moreover, Sales and Trading personnel may have acted on the basis of this material either on behalf of J.P. Morgan or, where permitted, in their personal accounts. As such, this material should not be relied upon as either objective or independent from the interests of J.P. Morgan and its associated personnel, which interests may conflict with your interests.
Securities, financial instruments or strategies mentioned herein may not be available in all jurisdictions or to all clients. Clients should contact their salespersons at, and execute transactions through, a J.P. Morgan entity appropriately licensed in the client’s home jurisdiction unless governing law permits otherwise.
Product names, company names and logos mentioned herein are trademarks or registered trademarks of their respective owners.
© 2022 JPMorgan Chase & Co. All rights reserved. J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide. Bank products and services, including certain lending, derivative and other commercial banking activities, are offered by JPMorgan Chase Bank N.A. (JPMCB), including through its authorized branches and other global affiliates registered with local authorities as appropriate. Securities products and services, including execution services, are offered in the United States and in other jurisdictions worldwide by J.P. Morgan Securities LLC (JPMS LLC), in EMEA by J.P. Morgan Securities plc (JPMS plc), J.P. Morgan AG (JPM AG) and by other appropriately licensed global affiliates. JPMCB, JPMS LLC, JPMS plc and JPM AG are principal subsidiaries of JPMorgan Chase & Co. For information on which legal entities offer investment banking products and services in each jurisdiction, please consult: www.jpmorgan.com/ib-legal-entities. For important disclosures in respect of securities transactions, please consult: www.jpmorgan.com/securities-transactions and in respect of over-the-counter equity derivatives transactions, please consult: www.jpmorgan.com/otc-equity-derivative-transactions.
Country Specific Disclosures
Brazil: J.P. Morgan Ombudsman: 0800-7700847. E-mail: ouvidoria.jp.morgan@jpmorgan.com.
Singapore: For important Singapore disclosures, please consult: https://www.jpmorgan.com/country/GB/EN/disclosures/apac-legal-entity-information#Singapore.
South Africa: J.P. Morgan Securities plc is exempt from the licensing provisions of the Financial Advisory and Intermediary Services Act, 2002.
For additional regulatory disclosures, please consult: www.jpmorgan.com/disclosures.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.